Daniel J. Figdore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel J. Figdore has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Algeciras-Schimnich
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
3 shared publications - Clifford R. Jack
Department of Radiology, Mayo Clinic, Rochester, MN; and
2 shared publications - David S. Knopman
Department of Neurology, Mayo Clinic, Rochester, MN
2 shared publications - Prashanthi Vemuri
Department of Radiology, Mayo Clinic, Rochester, MN; and
2 shared publications - Ronald C. Petersen
Department of Neurology, Mayo Clinic, Rochester, MN
2 shared publications Alicia Algeciras-Schimnich
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
1 shared publication
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218591
Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218591
Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200266
Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition
The APOE (apolipoprotein E) ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer disease (AD) and for brain amyloidosis, an early marker of disease pathophysiology. However, APOE ε4 is present in only 25% of the general population and is by itself inadequate for explaining susceptibility to amyloid accumulation or AD diagnosis. Existing studies have been limited by potential confounding due to inclusion of individuals carrying APOE ε4 or ε2 (which has a modest protective association). We hypothesized that genome-wide association study (GWAS) and genetic risk score (GRS) analyses in APOE ε3/ε3 individuals would uniquely identify novel predictors of β-amyloid pathology in older adults. We analyzed data from the Mayo Clinic Study of Aging (MCSA), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Rush Religious Orders Study and Memory and Aging Project. Frequency of APOE ε3/ε3 in those samples ranged from 48% to 61%. A GWAS was performed across 1,496 individuals with amyloid PET to identify candidate variants for GRS generation. Postmortem neuropathologic data (N = 710) were used to refine the variant list to capture high-likelihood true associations. An independent sample (N = 641) with plasma p-tau181 data was used for validation. The GWAS identified previously implicated (e.g., PICALM and RBFOX1) and novel potential associations with amyloid PET burden. A non-APOE GRS of top variants was strongly associated with amyloid PET levels in the MCSA (p = 4.34 × 10−9, β = 5.88) and ADNI (p = 1.87 × 10−8, β = 12.1) cohorts. In both cohorts, this non-APOE amyloid GRS outperformed a comparator GRS (based on variants associated with clinically diagnosed AD dementia risk) in explaining phenotypic variation. The non-APOE amyloid GRS was also associated with postmortem neuropathologic β-amyloid and neurofibrillary tangle burden and in an independent sample was associated with plasma p-tau181 concentrations (a robust indicator of cerebral amyloidosis). Our non-APOE amyloid GRS, which appropriately includes variants associated with amyloid deposition in APOE ɛ4/ɛ2 noncarriers, may advance personalized prediction of genetic susceptibility to β-amyloid accumulation within the large segment of the population that is APOE ε3/ε3. This may have future implications for risk modification, trial enrollment, and treatment selection.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200266
Open AccessCombating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition
The APOE (apolipoprotein E) ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer disease (AD) and for brain amyloidosis, an early marker of disease pathophysiology. However, APOE ε4 is present in only 25% of the general population and is by itself inadequate for explaining susceptibility to amyloid accumulation or AD diagnosis. Existing studies have been limited by potential confounding due to inclusion of individuals carrying APOE ε4 or ε2 (which has a modest protective association). We hypothesized that genome-wide association study (GWAS) and genetic risk score (GRS) analyses in APOE ε3/ε3 individuals would uniquely identify novel predictors of β-amyloid pathology in older adults. We analyzed data from the Mayo Clinic Study of Aging (MCSA), Alzheimer's Disease Neuroimaging Initiative (ADNI), and Rush Religious Orders Study and Memory and Aging Project. Frequency of APOE ε3/ε3 in those samples ranged from 48% to 61%. A GWAS was performed across 1,496 individuals with amyloid PET to identify candidate variants for GRS generation. Postmortem neuropathologic data (N = 710) were used to refine the variant list to capture high-likelihood true associations. An independent sample (N = 641) with plasma p-tau181 data was used for validation. The GWAS identified previously implicated (e.g., PICALM and RBFOX1) and novel potential associations with amyloid PET burden. A non-APOE GRS of top variants was strongly associated with amyloid PET levels in the MCSA (p = 4.34 × 10−9, β = 5.88) and ADNI (p = 1.87 × 10−8, β = 12.1) cohorts. In both cohorts, this non-APOE amyloid GRS outperformed a comparator GRS (based on variants associated with clinically diagnosed AD dementia risk) in explaining phenotypic variation. The non-APOE amyloid GRS was also associated with postmortem neuropathologic β-amyloid and neurofibrillary tangle burden and in an independent sample was associated with plasma p-tau181 concentrations (a robust indicator of cerebral amyloidosis). Our non-APOE amyloid GRS, which appropriately includes variants associated with amyloid deposition in APOE ɛ4/ɛ2 noncarriers, may advance personalized prediction of genetic susceptibility to β-amyloid accumulation within the large segment of the population that is APOE ε3/ε3. This may have future implications for risk modification, trial enrollment, and treatment selection.
- Open Access
- 16 January 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-8
Association of plasma biomarkers of Alzheimer’s pathology and neurodegeneration with gait performance in older adults
Background: Declining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). Methods: In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are associated with worse gait performance. A sample of 2641 Mayo Clinic Study of Aging participants with measurements of plasma biomarkers and gait parameters was analyzed in this cross-sectional study. Linear regression models using plasma biomarkers as predictors of gait parameters and adjusted for age, sex, BMI, Charlson Comorbidity Index, and cognitive diagnosis were evaluated. Results: In this study multiple statistically significant relationships are observed for GFAP, NfL, and P-Tau181 with gait parameters. Each standard deviation increase in GFAP, NfL, and P-Tau181 is associated with a reduction in velocity of 2.100 (95% CI: −3.004, −1.196; p = 5.4 × 10−6), 4.400 (−5.292, -3.507; p = 9.5 × 10−22), and 2.617 (−3.414, −1.819; p = 1.5 × 10−10) cm/sec, respectively. Overall, NfL has the strongest associations with poor gait performance. Models with age interactions show that the strength of associations between the plasma biomarkers and the gait parameters became stronger with increasing age. There are no specific gait parameters that associate with individual plasma biomarkers. Conclusion: Plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are not only markers of cognitive decline but also indicate motor decline in the aging population.
- 16 January 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-8
Open AccessAssociation of plasma biomarkers of Alzheimer’s pathology and neurodegeneration with gait performance in older adults
Background: Declining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). Methods: In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are associated with worse gait performance. A sample of 2641 Mayo Clinic Study of Aging participants with measurements of plasma biomarkers and gait parameters was analyzed in this cross-sectional study. Linear regression models using plasma biomarkers as predictors of gait parameters and adjusted for age, sex, BMI, Charlson Comorbidity Index, and cognitive diagnosis were evaluated. Results: In this study multiple statistically significant relationships are observed for GFAP, NfL, and P-Tau181 with gait parameters. Each standard deviation increase in GFAP, NfL, and P-Tau181 is associated with a reduction in velocity of 2.100 (95% CI: −3.004, −1.196; p = 5.4 × 10−6), 4.400 (−5.292, -3.507; p = 9.5 × 10−22), and 2.617 (−3.414, −1.819; p = 1.5 × 10−10) cm/sec, respectively. Overall, NfL has the strongest associations with poor gait performance. Models with age interactions show that the strength of associations between the plasma biomarkers and the gait parameters became stronger with increasing age. There are no specific gait parameters that associate with individual plasma biomarkers. Conclusion: Plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are not only markers of cognitive decline but also indicate motor decline in the aging population.